Chronic pain, by nature, is a multifaceted phenomenon that transcends the simplistic physical sensation typically measured in clinical settings. Conventional pain scales attempt to quantify suffering on a single dimension, yet pain’s impact extends to emotional well-being, social identity, and overall functional capability. Patients frequently express frustration that these scales obscure their true ordeal, reducing a complex narrative into an arbitrary number. This reductionism not only erodes patient trust but also challenges clinicians attempting to devise effective treatment plans grounded in incomplete data. Nirode’s article underscores this critical gap and introduces digital tools that aim to bridge it.

One of the most significant limitations of traditional pain assessment is recall bias. Patients often find it difficult to accurately remember and report the intensity or character of their pain days or weeks after an episode. Memory distortions, influenced by current mood or context, can skew responses, thus compromising clinical decisions. Furthermore, patients may consciously or unconsciously underreport symptoms due to concerns about stigma or being labeled drug-seeking. These psychological and social layers further distance clinical pain scores from the patient’s lived reality.

Emerging digital technologies promise to revolutionize pain assessment by capturing data in real time and integrating multiple dimensions of the pain experience. Among the forefront innovations is the Override platform, a virtual care app that seamlessly delivers patient-generated journals and tracking data directly into electronic medical records. By enabling continuous recording of pain fluctuations, triggers, and functional impact, Override transcends episodic snapshots, offering clinicians a dynamic and nuanced understanding of their patients’ condition.

Another groundbreaking tool highlighted by Nirode is Doctor Notes, an AI-powered scribe system that transcribes and summarizes doctor-patient interactions. This technology not only relieves clinicians from administrative burdens but creates a longitudinal contextual archive that retains subtle details often lost in conventional charting. By preserving verbal and nonverbal cues, Doctor Notes augments clinical insight and supports more personalized treatment strategies.

Perhaps the most striking innovation is PainChek, a digital facial recognition technology that objectively analyzes microexpressions to detect pain indicators even in patients unable to communicate verbally. Using sophisticated machine learning algorithms and computer vision, PainChek translates nuanced, involuntary facial movements into quantifiable pain metrics. This capability is transformative for vulnerable populations such as infants, nonverbal adults, and cognitively impaired patients, who have historically been under-assessed and undertreated.

Despite these promising advancements, the article candidly discusses the current disconnect between patient-collected digital data and formal medical records. Many healthcare institutions have yet to fully integrate these novel data streams into their electronic health records (EHR) systems, resulting in fragmentation and underutilization of valuable insights. Dr. Dimitri Souza of the Western Reserve Hospital Center for Pain Medicine pinpoints integration as the pivotal hurdle and the defining frontier for digital pain assessment’s future.

The article posits that healthcare’s gradual shift toward value-based care models will catalyze the widespread adoption of digital pain assessment technologies. Insurance reimbursement increasingly hinges on patient outcomes rather than service volume, incentivizing more comprehensive and continuous monitoring. Bridging traditional questionnaires with real-time digital metrics enables clinicians not only to treat pain symptoms but to address the broader impacts on patients’ identities, daily functioning, and quality of life.

Underlying these technological advancements is the principle that chronic pain should be understood as an embodied experience situated within complex ethical, psychological, and social contexts. Nirode’s reportage advocates for a biopsychosocial paradigm, where digital tools act as enablers of patient-centered care, fostering empathy, validation, and precision medicine. By capturing a richer data landscape, clinicians can challenge biases, tailor interventions, and ultimately improve outcomes for a notoriously underrepresented patient population.

In conclusion, “The Need for Continued Investment in Digital Pain Assessment” serves as a clarion call for the healthcare community to reimagine pain measurement through the lens of innovation, integration, and inclusivity. Digital tools such as Override, Doctor Notes, and PainChek exemplify the potential to disrupt entrenched methodologies and transform subjective pain into actionable intelligence. Yet realizing this potential demands concerted effort to bridge technological capabilities with healthcare infrastructure and incentivize adoption through policy and reimbursement reforms.

As our understanding of pain evolves beyond simple numeric scales, so too must our commitment to developing tools that truly reflect the patient’s journey. Nirode’s incisive analysis and the sophisticated technological solutions she highlights illuminate a path forward—one where assessment transcends symptoms, embraces the whole person, and ultimately leads to meaningful relief for millions burdened by chronic pain.

—

Subject of Research: People

Article Title: The Need for Continued Investment in Digital Pain Assessment

News Publication Date: 17-Apr-2026

Web References: Not provided

References: Nirode V. The Need for Continued Investment in Digital Pain Assessment. J Med Internet Res 2026;28:e97777. DOI: 10.2196/97777

Image Credits: Vanessa Nirode, JMIR Correspondent

In a groundbreaking study led by Associate Director WOO Choong-Wan at the Center for Neuroscience Imaging Research within the Institute for Basic Science, the scientific community has witnessed a pioneering advance in the search for a robust, individualized biomarker for chronic pain. Collaborating with Professor CHO Sungkun’s team at Chungnam National University, the researchers have harnessed the potential of personalized brain imaging combined with machine learning to decode the complex fluctuations of spontaneous pain in fibromyalgia patients—a group typified by diffuse and relentless pain without clear external cause.

Fibromyalgia, characterized by widespread spontaneous pain, was chosen as the model condition for this intensive longitudinal investigation. Over an extended period exceeding six months, participants underwent repeated functional magnetic resonance imaging (fMRI) sessions, a technique that measures cerebral blood oxygen level-dependent signals and thus offers insight into dynamic neural activity. During scanning, patients continuously reported their subjective pain levels, enabling the researchers to amass a rich, densely sampled dataset linking real-time brain function with fluctuating pain experience.

The crux of this study lies in applying advanced machine learning algorithms to these extended fMRI datasets. Unlike prior studies focusing on discrete brain regions, this research leveraged whole-brain functional connectivity, mapping the interactions among distributed neural networks implicated in pain processing. Such comprehensive mapping allowed the creation of individualized brain decoding models capable of predicting moment-to-moment pain intensity with remarkable precision across multiple temporal scales—from swift minute-level changes within single sessions to broader variations spanning days and weeks.

Interestingly, the study illuminated a critical insight: the neural signatures of chronic pain are highly individualized. The models trained on one participant’s brain data failed to generalize to others, underscoring the distinct neurobiological underpinnings shaping each person’s pain experience. This finding dismantles the long-held hope for universal brain-based pain markers and accentuates the necessity of precision neuroimaging tailored to the individual’s unique pain connectome, a concept describing the personalized pattern of brain connectivity that sustains their chronic pain.

One of the methodological breakthroughs revealed by this work is the paramount importance of extensive within-person data sampling. Traditional neuroimaging studies often rely on limited datasets, insufficient to capture the nuanced and fluctuating nature of spontaneous pain. Including ample longitudinal data markedly enhanced prediction accuracy, indicating that only through rich, repeated brain imaging coupled with continuous pain reporting can reliable personalized biomarkers be constructed—a revelation with profound implications for both scientific research and clinical practice.

This precision neuroimaging protocol sets a new standard, moving away from generalization toward bespoke pain profiling. The dense longitudinal approach provides a powerful tool to track the spontaneous and ephemeral nature of chronic pain and opens avenues toward objective, real-time pain assessment, a dramatic shift from subjective questioning toward quantifiable brain-derived metrics. Future extensions of this research may lead to non-invasive diagnostics and personalized therapeutic monitoring, transforming chronic pain care by enabling targeted interventions tuned to each patient’s unique neural pain architecture.

Moreover, these findings prompt reevaluation of the neurological complexity of chronic pain. That brain connectivity patterns differ so widely among individuals provokes questions about underlying biological variability—possible genetic, neurochemical, or environmental contributors—that dictate distinct pain processing pathways. Establishing such mechanistic insights is essential to classify chronic pain subtypes, which could refine diagnosis and optimize individualized treatment regimens in the emerging era of precision medicine.

Despite its promise, this research acknowledges limitations that warrant attention. The sample size was modest, and participants were exclusively fibromyalgia patients, prohibiting immediate clinical application. Nevertheless, the study provides a powerful methodological framework that invites replication and extension across broader, heterogeneous cohorts to determine if shared neural features exist among different chronic pain syndromes or if each case demands a uniquely tailored solution based on idiosyncratic brain network patterns.

Technically, the employment of whole-brain fMRI functional connectivity matrices in conjunction with machine learning represents a sophisticated integration of neuroimaging and computational modeling. The models capture complex, non-linear interactions across brain regions, demonstrating superior temporal resolution in decoding pain fluctuations compared to conventional region-of-interest analyses. This holistic analytic strategy could revolutionize how brain imaging data is interpreted beyond pain research, offering insights into other spontaneous subjective phenomena currently inaccessible to objective measurement.

At the forefront of this innovation is Dr. WOO Choong-Wan, who emphasizes the transformative potential of seeing the “invisible” pain. By translating neural signatures into objective pain estimates, this approach may alleviate an essential clinical dilemma: validating and quantifying the otherwise intangible suffering of chronic pain patients. Additionally, LEE Jae-Joong, lead author, highlights that personalized neural signatures could tailor pain management strategies, reducing trial-and-error approaches and enhancing efficacy.

This study’s publication in Nature Neuroscience signals a milestone, opening a new frontier to decode the brain’s spontaneous pain signaling through precision neuroimaging. While technical and translational hurdles remain, the pathway is illuminated toward personalized pain biomarkers that may one day fundamentally reshape diagnostics, patient care, and our understanding of the human brain in health and disease.

In conclusion, this work heralds a paradigm shift—ushering in an era where invisible chronic pain could be measured directly from the brain’s unique connectome. The fusion of intensive longitudinal neuroimaging with machine learning not only promises to deepen insights into chronic pain’s neural basis but also lays foundational stones for precision diagnostic tools and individualized therapies. As research continues to unravel the intricate tapestry of personalized brain pain networks, the vision of objective, brain-based pain assessment is coming into clearer focus—offering hope for millions who currently endure pain that remains frustratingly unseen and untreated.

Subject of Research: People

Article Title: Personalized brain decoding of spontaneous pain in individuals with chronic pain

News Publication Date: 26-Feb-2026

Web References: 10.1038/s41593-026-02221-3

Image Credits: Institute for Basic Science

Keywords: Chronic pain, Pain, Symptomatology, Diseases and disorders, Functional magnetic resonance imaging, Functional neuroimaging, Neuroimaging, Imaging, Research methods, Fibromyalgia, Longitudinal studies, Observational studies, Brain, Central nervous system, Nervous system, Anatomy, Organismal biology, Life sciences

EAET, developed in the 2010s, is predicated on the understanding that chronic pain is not merely a physiological phenomenon but intricately tied to the brain’s processing of stress-related emotions. The therapy operates on the premise that pain perception is a neurobiological process influenced at multiple levels by unresolved emotional conflicts and stressors. Unlike classic CBT, which primarily addresses maladaptive thought patterns, EAET facilitates patients in recognizing and processing emotional stressors—ranging from everyday life irritations to profound traumas—aiming to rewire neural circuits that link emotion and pain perception.

The upcoming NIH-funded clinical trial represents one of the most ambitious attempts to validate EAET’s therapeutic potential in a real-world clinical environment. Over the course of five years, this large-scale pragmatic trial will enroll approximately 700 older war veterans across seven geographically diverse U.S. Department of Veterans Affairs centers. These sites will serve as testing grounds to assess both the efficacy and practicality of EAET, with the hope of demonstrating scalability for widespread clinical adoption tailored for the veteran population, a group disproportionately affected by chronic pain syndromes.

Leading the charge is Dr. Brandon Yarns, an assistant professor at UCLA Health’s Department of Psychiatry and Biobehavioral Sciences, whose prior research laid the foundation for this pivotal trial. Notably, Dr. Yarns’ earlier study involving 126 veterans was the first comprehensive clinical investigation of EAET specifically targeting older men within the military demographic. That study revealed that 63% of participants receiving EAET achieved significant reductions in chronic pain, compared to only 17% in those subjected to traditional cognitive behavioral therapy. This stark differential underscores EAET’s transformative potential in reshaping chronic pain interventions.

One of the critical scientific insights underpinning EAET is the recognition of the brain’s plasticity concerning pain pathways. Chronic pain often becomes entrenched as maladaptive neural circuits reinforce pain signals, a process exacerbated by unaddressed psychosocial stressors. EAET leverages therapeutic techniques designed to help patients confront and emotionally process these stressors, facilitating neurocognitive changes that diminish the intensity and persistence of pain signals. This approach moves beyond symptom management towards addressing root causes embedded in the brain’s emotional processing systems.

The study design is meticulously structured to ensure robust and clinically relevant results. The first year of the trial will focus on site preparation, clinician training, and comprehensive interviews with participating veterans to tailor the therapeutic protocol effectively. The four subsequent years will involve administering EAET in practical clinical settings, monitoring patient outcomes, and refining methodologies to optimize treatment delivery. Collecting real-world data on effectiveness, adherence, and patient satisfaction will be crucial for translating research findings into standard care practices.

Veterans constitute a uniquely challenging cohort for chronic pain research due to the elevated exposure to physical injuries and psychological trauma such as combat-related stress and post-traumatic stress disorder (PTSD). EAET’s focus on emotional processing makes it especially suited to address this interplay between psychological trauma and somatic pain experiences. By targeting the affective dimension of pain, the therapy aims to break the vicious cycle where emotional distress amplifies pain perception, subsequently worsening mental health and quality of life.

From a neurobiological perspective, EAET interventions engage brain regions implicated in emotion regulation and pain modulation, including the anterior cingulate cortex, amygdala, and prefrontal cortex. Emerging neuroimaging studies hint at alterations in connectivity and functional activation patterns associated with emotional disclosure and expression, providing empirical support for the therapy’s mechanistic hypotheses. These findings suggest that emotional processing not only serves psychological relief but induces tangible changes in central nervous system activity related to pain experience.

The potential implications of EAET extend far beyond the veteran population. Chronic pain affects a substantial portion of the aging population worldwide, often resistant to pharmacological treatments and burdened by side effects. If this five-year trial corroborates earlier findings, EAET may be integrated into geriatric pain management protocols, offering a non-pharmacological, scalable, and patient-centered approach that addresses the multidimensional nature of chronic pain in older adults.

Moreover, EAET’s emphasis on emotional processing aligns with contemporary shifts in psychological treatment frameworks that advocate for trauma-informed care. By acknowledging and therapeutically targeting the emotional antecedents of pain, EAET offers a paradigm that is congruent with holistic models of health that consider the biopsychosocial dimensions of disease. This approach resonates with broader mental health initiatives aimed at improving functional outcomes and reducing chronic disability.

Despite the promising outlook, several challenges remain as this therapy moves into wider clinical application. Training sufficient numbers of clinicians in EAET’s specialized techniques, ensuring fidelity of implementation, and addressing variability in patient emotional readiness and engagement will be critical factors influencing scalability and effectiveness. The planned clinical trial’s pragmatic design is particularly well-suited to uncovering and addressing these translational hurdles.

In summary, UCLA Health’s new NIH-funded clinical trial embodies a significant leap forward in chronic pain research. By rigorously testing emotional awareness and expression therapy among a large and diverse veteran cohort, the research aims to validate a treatment modality that not only alleviates pain more effectively than traditional cognitive behavioral therapy but also targets its neuropsychological underpinnings. This work stands to fundamentally alter the landscape of chronic pain management, offering hope to millions of older adults wrestling with persistent pain rooted in complex emotional experiences.

The forthcoming results of this comprehensive study will likely generate wide-reaching interest across medical, psychological, and veteran care communities. Success in this arena could catalyze a paradigm shift emphasizing emotional processing as a cornerstone of chronic pain treatment, potentially encompassing other conditions where psychosocial factors play a decisive role. As such, EAET at UCLA Health symbolizes a convergence of cutting-edge neuroscience, innovative psychotherapy, and compassionate clinical care designed to transform how chronic pain is understood and treated in aging populations.

Subject of Research: Emotional awareness and expression therapy (EAET) for chronic pain management in older veterans

Article Title: UCLA Health Launches Landmark NIH-Funded Clinical Trial Exploring Emotional Awareness and Expression Therapy to Alleviate Chronic Pain in Older Veterans

News Publication Date: June 2024

Web References:
– NIH Clinical Trial Details: https://reporter.nih.gov/search/3E6H7MI-JUiMjX3jpWFLiA/project-details/11229006
– Prior Research Publication: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2819961?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=061324

Keywords: Chronic pain, Psychiatry, Emotions, Older adults, War, Warfare